5 June 2023
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology", "Cizzle" or the "Company")
Posting of Annual Report and Notice of AGM
Cizzle Biotechnology, the UK-based diagnostics developer, is pleased to announce that copies of the annual report and accounts for the year ended 31 December 2022, together with the notice of Annual General Meeting ("AGM"), have been sent to shareholders and are available for viewing on the Company's website at https://cizzlebiotechnology.com.
The AGM of Cizzle Biotechnology will be held at 11.00 a.m. BST on 28 June 2023 at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR.
Enquiries:
| Cizzle Biotechnology Holdings plc | Via IFC Advisory |
| Allan Syms (Executive Chairman) | |
| Allenby Capital Limited | +44(0) 20 33285656 |
| John Depasquale | |
| Alex Brearley | |
| Novum Securities Limited | +44(0) 20 7399 9400 |
| Colin Rowbury Jon Bellis | |
| IFC Advisory Limited | +44(0) 20 3934 6630 |
| Tim Metcalfe | cizzle@investor-focus.co.uk |
| Florence Chandler | |
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see https://cizzlebiotechnology.com You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.